ALDR anyone? A migraine treatment developed by Washington-based Alder Biopharmaceuticals appeared to deliver less of a benefit over placebo than rival drugs, sending shares in the biotech down more than 20% in early Tuesday trading even though the Phase 3 study met its goal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.